Feb 28 (Reuters) - Bellus Health Inc BLU.TO
* Bellus Health and the NEOMED Institute announce an exclusive worldwide license agreement for the development of a treatment for chronic cough
* Under terms of agreement, Bellus Health will pay neomed an upfront fee of cad $3.2 million
* Upfront fee consists of CAD $1.7 million in cash and CAD $1.5 million with 5.8 million bellus health common shares
* As per agreement, NEOMED will be entitled to receive a royalty on net sales-based revenues Source text for Eikon: ID:nCNW93VmYa Further company coverage: BLU.TO